Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
CARBOPLATIN
Ebewe Pharma Ges.m.b.H Nfg. KG
CARBOPLATIN
10 Mg/Ml
Concentrate for Soln for Inf
Authorised
0000-00-00
(IE/H/0134/001/IB/012) 1.3.1 spc-label-pl - common-pl - 3,971 PACKAGE LEAFLET: INFORMATION FOR THE USER CARBOPLATIN "EBEWE" 10 MG/ML - CONCENTRATE FOR SOLUTION FOR INFUSION Carboplatin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE. • Keep this leaflet. You may need to read it again. • If you have further questions, please ask your doctor or pharmacist. • If you get any of the side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. IN THIS LEAFLET: 1. What Carboplatin Ebewe is and what it is used for 2. Before you are given Carboplatin Ebewe 3. How you are given Carboplatin 4. Possible side effects 5 How to store Carboplatin Ebewe 6. Contents of the pack and other information 1. WHAT CARBOPLATIN EBEWE IS AND WHAT IT IS USED FOR The drug Carboplatin Ebewe is used to treat different types of cancer, like lung cancer and cancer in the ovaries. It can be used alone but more commonly it is used in combination with other anti-cancer agents. 2. BEFORE YOU ARE GIVEN CARBOPLATIN EBEWE YOU SHOULD NOT BE GIVEN CARBOPLATIN EBEWE: • If you are hypersensitive (allergic) to Carboplatin or any of the other ingredients of Carboplatin Ebewe. • If you are pregnant or breast-feeding • If you suffer from severe myelosuppression (very low number of platelets in the blood) • If your kidneys are not working properly • If you cannot hear well If any of these apply to you and you have not already discussed this with your doctor or nurse, you should do so as soon as possible and before receiving Infusion. This agent will only be administered under the direction of an oncologist, in specialist units under condi Baca dokumen lengkapnya
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Carboplatin "Ebewe" 10 mg/ml Concentrate for Solution for Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the concentrate contains 10 mg Carboplatin. Each vial of 5 ml of the concentrate contains 50 mg Carboplatin. Each vial of 15 ml of the concentrate contains 150 mg Carboplatin. Each vial of 45 ml of the concentrate contains 450 mg Carboplatin. Each vial of 60 ml of the concentrate contains 600 mg Carboplatin. Each vial of 100 ml of the concentrate contains 1000 mg Carboplatin. Excipients with known effect : For the full list of excipients, see 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion. A clear, colourless or almost colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Carboplatin is used alone or in combination with other antineoplastic agents in the treatment of advanced ovarian carcinoma and small cell (SCLC) and non-small cell lung carcinoma (NSCLC). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Carboplatin injection should be used by the intravenous route only. The recommended dosage of carboplatin injection in previously untreated adult patients with normal kidney function is 400 mg/m 2 as a single intravenous dose administered by a 15- to 60-minute infusion. Therapy should not be repeated until 4 weeks after the previous carboplatin injection course and/or until the neutrophil count is at least 2,000 cells/mm 3 and the platelet count is at least 100,000 cells/mm 3 . Reduction of the initial dosage by 20-25% is recommended for those patients who present with risk factors such as prior myelosuppressive treatment and low performance status (ECOG-Zubrod 2-4 or Karnofsky below 80). Determination of the hematologic nadir by weekly blood count during Baca dokumen lengkapnya